肾小球滤过率下降作为心力衰竭临床试验终点的挑战与解决方案
慢性肾病与心衰常共存,评估CKD进展对患者管理和试验终点均重要。本文阐述心衰与CKD交叉领域,讨论GFR及其变化在个体和干预试验中的评估方式,支持将GFR变化作为CKD进展试验终点的证据,以及将其用于心衰结局试验和个体化管理的挑战与可能的解决方案,并以案例研究引导讨论。
要点
- 心衰结局试验中可采用GFR斜率或特定阈值百分比(40%或50%)的GFR下降时间作为CKD进展的替代终点。
- 监管机构已接受这些终点用于CKD进展药物的完全批准,将其应用于心衰结局试验有望取得类似进展。
- 心衰指南导向治疗后常出现GFR即刻下降,需区分即刻下降与长期肾脏获益以优化终点评估和患者管理。
核心结论
- 将GFR下降(斜率或特定阈值百分比下降时间)作为心衰结局试验终点具有潜力,但需正确解读指南导向治疗后的GFR即刻下降与长期肾脏获益。
研究设计与样本
- 本文为综述性文章,描述心衰与CKD的交叉、GFR及其随时间变化在个体患者和干预试验中的评估方式,以及支持GFR变化作为CKD进展试验终点的证据,并以案例研究引导讨论。
主要发现
- 心衰结局试验持续时间相对较短,在需要肾脏替代治疗的临床事件发生前,早期CKD进展指标(如GFR斜率或40%或50%的GFR下降时间)是可取的替代指标。
- 监管机构接受这些终点用于CKD进展药物的完全批准,已促进该领域试验设计与实施的进展。
- 启动多种心衰指南导向治疗后即刻GFR下降常见,需理解其与长期肾脏获益的区别。
关键数值与推荐
- GFR斜率按年化平均GFR变化计算,或采用达到特定阈值百分比(40%或50%)GFR下降的时间作为替代终点。
临床怎么用
- 在心衰患者个体评估和结局试验中,可考虑使用GFR斜率或40%/50% GFR下降时间评估CKD进展。
- 启动心衰指南导向治疗后出现GFR即刻下降时,需区分其与长期肾脏获益,以优化治疗管理和终点解读。
局限性
- 心衰结局试验持续时间相对较短,需依赖早期CKD进展替代指标而非肾脏替代治疗等临床事件。
- 指南导向治疗后GFR即刻下降的解读存在挑战,需进一步区分即刻下降与长期肾脏获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) and cardiovascular disease are tightly interconnected, with common mechanisms that underlie the development and progression of both diseases, recently articulated into the framework of the cardiovascular-kidney-metabolic syndrome. CKD and heart failure commonly coexist in the same individual, with increasing evidence for common therapies in both disease states. It is valuable for patients, clinicians, and regulatory agencies to understand how to best assess CKD progression in patients with heart failure for evaluation of individual patients and as part of an endpoint for outcome trials. Given the relatively short duration of most heart failure outcome trials, early measures of CKD progression prior to the occurrence of clinical events of kidney replacement therapy would be desirable. Such surrogate measures include slowing of the decline in glomerular filtration rate (GFR) decline either computed as annualized mean change in GFR (GFR slope) or time to substantial declines in GFR by specified threshold percentages (40% or 50% GFR decline). Regulatory agencies accept these endpoints for full drug approval which has enabled progress in design and conduct of trials for CKD progression. Application of these endpoints in heart failure outcome trials has the potential for similar progress. However, an immediate reduction in GFR is common following initiation of several of the guideline directed therapy for heart failure. Understanding how to best interpret an immediate GFR reduction vs long term kidney benefit is critical to optimal assessment of endpoint in an outcome trial and in the use of these medications for management of patients with heart failure. Here, the intersection of heart failure and CKD is described, how GFR and its change over time are assessed in both individual patients and in interventional trials, the evidence supporting use of GFR changes as endpoints in CKD progression trials, and the challenges and possible solutions for the use of GFR as endpoint in heart failure outcome trials and for care of individual patients, guided by case studies to inform the discussion.
引用
- Inker LA, Neuen BL, McCallum W, et al. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. Eur Heart J. 2025. PMID: 40905476. doi:10.1093/eurheartj/ehaf591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。